Study of Lactase Enzyme Supplements to Prevent Feeding Intolerance in Preterm Babies Born at 32 Weeks or Earlier

What this Trial Is About

Researchers are evaluating the effect of lactase enzyme supplements in preventing feeding intolerance among preterm newborns in a neonatal intensive care unit. The study focuses on preterm neonates born at or before 32 weeks gestational age who start feeding within the first 72 hours of life. This research is important to understand how lactase enzyme may support feeding in these vulnerable infants. Participants will be randomly assigned to receive either lactase enzyme drops added to their formula milk or a placebo with no lactase. The lactase group will receive one drop per 10 ml of formula for 14 days. The control group will receive 10 ml of milk without lactase. The study includes a 14-day treatment period starting shortly after feeding begins. During the study, researchers will monitor feeding intolerance during the first two weeks of life. Assessments will include careful observation of feeding tolerance, clinical status, and any complications. The study will follow infants closely with routine evaluations to measure the main outcome related to feeding tolerance. The total duration of participation aligns with the initial two weeks of feeding after birth.

Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates